ArticleBMC infectious diseases2025
The overuse of antimicrobials during the COVID-19 pandemic: data from 25 general hospitals in Shanxi, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Longitudinal Exploratory Study of SARS-CoV-2 Antibody Dynamics in Young Adults in Bogotá: Lessons from Natural Infection and Post-Vaccination Memory.Biomedicines · 2026Article
- Knowledge, Attitudes, and Practices Regarding Infection Prevention Among Healthcare Professionals and Their Predictors at a Tertiary Hospital in Ethiopia: A Cross-Sectional Study.Health science reports · 2026Article
- Early antibiotic review and AWaRe prescribing in respiratory infections before vs during COVID-19: a two-hospital retrospective cohort study.Journal of pharmaceutical policy and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDuring the coronavirus disease 2019 (COVID-19) pandemic, widespread empirical antimicrobial use was reported globally, often without confirmed bacterial infection. This study aimed to assess antimicrobial prescribing patterns, bacterial coinfection rates, and clinical outcomes among inpatients during the Omicron surge in Shanxi Province, China.
methodsWe conducted a multicentre retrospective study using data from 25 hospitals. Non-surgical inpatients discharged between December 1, 2022, and January 31, 2023, were included. Patients were categorized by COVID-19 status and antimicrobial use. Antimicrobial consumption was measured using defined daily doses (DDDs), days of therapy (DOT), and antimicrobial use density (AUD). Clinical outcomes, microbiological data, and adverse events were analyzed.
resultsAmong the 2064 inpatients included, 701 (34.0%) were diagnosed with COVID-19. Of these, 511 (72.9%) received antimicrobial therapy, while only 382 (54.5%) had a documented bacterial infection. Microbiological testing was positive in only 123 (6.0%) patients, yielding 139 isolates, of which 21 (15.1%) were multidrug-resistant. Consistently, COVID-19-positive patients were exposed to broad-spectrum agents more frequently: the proportions of both highly-restricted and restricted antimicrobials were significantly higher than in COVID-19-negative patients (4.7% vs. 2.8% and 68.2% vs. 61.9%, respectively; P < 0.05). Overall antimicrobial pressure was also greater in the positive group: antimicrobial-use density reached 84.28 vs. 47.07 DDDs/100 bed-days (P < 0.001), and days of therapy were 811.06 vs. 541.43 /1000 patient-days (P < 0.001). These differences translated into higher costs (median total hospitalization expense CNY 8013 vs. CNY 6447; P < 0.001) and prolonged stays (36.0% stayed 11–20 days vs. 22.4%; P < 0.001). Mortality did not differ across groups (P = 0.779).
conclusionThis study highlights the excessive use of antimicrobials in COVID-19 inpatients, often without confirmed bacterial infection. This overuse did not improve outcomes but contributed to increased healthcare costs and antimicrobial resistance risk. Rational antimicrobial management and improved diagnostic practices are crucial to combat this challenge in health care settings. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.